Free Newsletter
Microsoft
Microsoft
The Windows Azure platform, first announced in October 2008, had its business and partner model debut last month. Some cloud capabilities appeared earlier, in Microsoft's Silverlight 3 Beta and Expression Blend 3 Preview platforms.
Azure includes a cloud services operating system, a Web-based relational database in Microsoft SQL Azure, and connectivity and interoperability with .NET Services. The platform combines cloud-based developer capabilities with storage, computational and network infrastructure services hosted on servers in Microsoft's global datacenter network.
- Security: SQL is built on SQL Server technology, which incorporates enterprise-level security features.
- Agility: Developers can deploy applications in the cloud, on-premises, or in combination.
- Cost elements: Pricing is pay-as-you-go, backed by service-level agreements. Once Windows Azure is launched for commercial use, it will be priced and licensed through a consumption-based model:
- Windows Azure:
- Compute: $0.12 / hour
- Storage: $0.15 / GB stored / month
- Storage Transactions: $0.01 / 10K
- Bandwidth: $0.10 in / $0.15 out / GB
- SQL Azure:
- Web Edition, to 1 GB relational database: $9.99 / month
- Business Edition, to 10 GB relational database: $99.99 / month
- Bandwidth: $0.10 in / $0.15 out / GB
- Windows Azure:
- Biopharma suitability: Suited to building applications, with Visual Studio, the .Net Framework, SQL Server in the form of SQL Azure, and Microsoft SharePoint, then run the resulting cloud application in Azure itself.
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




